caulfield12

Are we talking the CDC botched tests that were measuring something that wasn’t even necessary or all the public/private lab and drug companies?

Imagines how many cases without absentee voting...

Well, at least Burdi looked better and Robert drew a walk.

The Cardinals Bottom 5 in MLB with Anheuser Busch ties? Interesting four of the last six California-based teams. SF, everything is too/so expensive, plus the whole late to arrive, early to leave thing going on.

https://www.mlb.com/news/cj-abrams-showing-padres-he-deserves-top-prospect-status?partnerId=zh-20210305-156906-MLB&qid=1026&bt_ee=tr9SnwjNRENqfe%2FL8uyYzJ%2FXY0aF1abJpWwlL%2FnTbQSriRYrFkrlKt9v5zCnd48j&bt_ts=1614947885224

That said, unless they substantially suppress the characteristics of the game ball, Vaughn's going to be to good for 25-35, touching 40 homers per season on a pretty consistent basis...regardless of what happens in March/Arizona. Pete Alonso with slightly less homers but a better average and OBP/walk rate seems pretty likely, although obviously not guaranteed, and obviously Alonso had his share of struggles statistically (analytics-wise, he was better in some ways, without the results to show it.)

And he was actually much worse than everyone was expecting, like Jo Adell...Casey Mize, etc.

https://www.yahoo.com/sports/white-sox-mvp-jos-abreu-010922346.html

Kolten Wong was a decent comp in terms of value. The type of player you really need, who isn't worth something like $8-9 million in arbitration to a mid-market team like the Cardinals but certainly provides a good value to those Top 10-12 teams payroll-wise who can afford to carry a salary like that. Ironic, is that the Brewer generally run an even tighter ship financially than the Cardinals. In that case, seemed they prioritized keeping the likes of Wainright and Molina in the fold.

Yes, only if you have one of those "generational" talents at that position, rather than roughly league average. Then giving an early extension really isn't worth it, especially without plus defense to go with it. If he's a Frank Thomas or even Abreu (granted, the middle part of his Sox career didn't live up to the first two years until 2020)...then you have to pursue it. Yes, pretty obvious observations. The problem, of course, is not knowing how close he's going to eventually end up to those two (now) historical Sox names.

Madrigal should be in that category with Kopech/Cease/Crochet where you see exactly where they are at performance and health-wise after this season is over. Any/all efforts should be directed at Giolito (seems unlikely) or Vaughn right now.

That said, look at where the Cubs are with their four "studs." Bryant and Baez have substantially diminished value. They could still get a really nice return for Contreras, but certainly not what it would have been from 2016-18. They got nothing out of Schwarber and Almora, and the Soler for Davis deal went the wrong way as well. Happ is pretty much the only prospect who's still remaining from those classes, unless you count Bote. Then they pretty much have to keep Rizzo and Hendricks to have at least two established Cubs' veterans to market.

Beckham Viciedo Marcus Semien (with White Sox) Brian Anderson Those are the main "busts" from the last decade plus. Rowand and Crede are about all we produced internally for almost a decade, and it took them a good 2-3 seasons to win the starting jobs. Of course, Joe Borchard comes to mind, but now we're going back almost 20 years.

J&J’s efficacy rate falls short compared to those of Pfizer (PFE) and Moderna (MRNA). Johnson and Johnson’s vaccine is 72% in preventing moderate-to-severe COVID-19 in the U.S., compared to Pfizer and Moderna’s efficacy rates of 95% and 94%, respectively, in preventing symptomatic disease. But don’t let the headline numbers discourage you, as it is not an apples-to-apples comparison. Johnson & Johnson’s vaccine was found to be 85% effective against severe COVID, similar to Moderna and Pfizer. ... Despite production delays, Johnson & Johnson does have an edge over Pfizer and Moderna when it comes to distribution. One big advantage is that Johnson & Johnson’s vaccine can be stored in a refrigerator for up to three months, compared to Pfizer and Moderna vaccines which must be stored at freezing temperatures. “I think it's incredible news for all of us… There are many advantages to a single-shot vaccine that can be stored in much warmer temperatures,” said Hathi. https://finance.yahoo.com/news/johnson-and-johnson-single-dose-vaccine-is-absolutely-a-game-changer-vaccinations-to-pick-up-171204467.html

No doubt the perception of J&J is a full 1/2 tier below.... minus the unique refrigeration conditions for the other two leaders in terms of efficacy. The J&J is closer to the roughly 70~80% effectiveness range?